Login to Your Account

Melanoma drug Keytruda gets first FDA nod for PD-1 inhibitor class

By Jennifer Boggs
Managing Editor

Thursday, September 4, 2014

Rumors of an early approval for Merck & Co. Inc.'s high-profile PD-1 inhibitor Keytruda (pembrolizumab) turned out to be no exaggeration, as the FDA gave its nod to the drug Thursday for use in patients with advanced or unresectable melanoma who are no longer responding to other drugs.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription